Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept
Other Research AreasDecapeptide corresponding to the C-terminal region of human kisspeptin (metastin residues 45–54)

Kisspeptin-10

Kisspeptin-10 is studied as a decapeptide corresponding to the c-terminal region of human kisspeptin (metastin residues 45–54) in biochemical and physiological models.

Category 2Preclinical Models Only (Animal / Lab)Also known as: KP-10, Metastin (45-54)Skip to Human Evidence ↓
Other Research Areas

Kisspeptin-10 Biological Classification

Research Record

Investigated within physiological and chemical models.

At a glancePlain English, then the evidence
Not graded

What kind of compound

Peptide

Decapeptide corresponding to the C-terminal region of human kisspeptin (metastin residues 45–54).

Human testing on file

0human records

0 animal · 0 total indexed. No plain-English evidence summary on file.

Regulatory position

FDA compounding Category 2

Studied for

Peptide fragments

Reviewed 15 September 2026

Known safety concerns in this file

  • No sourced human safety summary is recorded for this compound.

Commonly compared with

No comparison set is recorded for this compound yet.

Open side-by-side comparison →
1

What is Kisspeptin-10?

Kisspeptin-10 is classified as a decapeptide corresponding to the c-terminal region of human kisspeptin (metastin residues 45–54). A decapeptide fragment of human kisspeptin with no FDA-approved drug product. It is on FDA's active 503A Category 2 table for bulk substances used in compounding, and kisspeptin and its agonist analogues are prohibited in sport under WADA class S2.2.1.

2

Why are people interested in it?

Researchers and clinicians study Kisspeptin-10 primarily to understand its biological interactions, receptor binding affinity, and potential role within its biochemical class.

Primary Research Categories

  • Peptide fragments
  • Kisspeptins
3

How does it work in the body?

Kisspeptin-10 interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a decapeptide corresponding to the c-terminal region of human kisspeptin (metastin residues 45–54).

In Everyday Language: In laboratory settings, Kisspeptin-10 interacts with specific cellular targets to modulate biological signaling pathways associated with decapeptide corresponding to the c-terminal region of human kisspeptin (metastin residues 45–54) biology.
Cellular & Receptor Signaling: Kisspeptin-10 interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a decapeptide corresponding to the c-terminal region of human kisspeptin (metastin residues 45–54).

Biological Pathway Overview

Kisspeptin-10 Receptor & Target Interactions

This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.

Target Pathway

Engages specific cellular signaling cascades characteristic of its structural family.

Endocrine/Paracrine Activity

Investigated for its regulatory effects on local tissue synthesis and cellular signaling.

4

What has actually been demonstrated in humans?

Preclinical Models Only (Animal / Lab)

Evidence for Kisspeptin-10 is currently derived primarily from laboratory or preclinical models. Consult the published evidence file for specific indexed studies.

Pharmaceutical Reality vs. Unregulated Research Chemicals

Kisspeptin-10 is not an FDA-approved medication. Always verify chemical identity and testing documentation before interpreting research literature.

5

What is still uncertain or unknown?

Controlled human clinical trials evaluating Kisspeptin-10 for therapeutic efficacy, safety, and pharmacokinetics are limited or absent in peer-reviewed Western registries.

Regulatory Position: Kisspeptin-10 is an investigational or unapproved compound. It is not approved by the FDA as a commercial pharmaceutical.

Companion Resources & Guides

Evidence Landscape→

Primary research publications and study designs indexed for Kisspeptin-10.

Research at a Glance

Open the full evidence file (0 records)

No evidence records in this file yet.

What Has Actually Been Studied

    What is Still Unknown

    What we know

      Editorial reading of the records below, labelled as Therapept analysis. How records are built

      What remains uncertain

        Preparation and Handling

        Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.

        Preparation Resource HubWhat “lyophilized” meansConcentration calculator

        United States Regulatory Status

        FDA compounding Category 2

        • No approved drug product exists in Drugs@FDA.
        • Kisspeptin-10 is on FDA's active Category 2 table for 503A compounding, added 29 September 2023. FDA's published concerns are immunogenicity risk for certain routes, peptide-related impurities and API characterisation, and no or limited safety information for the proposed routes.
        • ClinicalTrials.gov lists registered human studies of kisspeptin. Registration is not approval.

        WADA Anti-Doping Status

        Named at S2.2.1 — “kisspeptin and its agonist analogues”, among testosterone-stimulating peptides in males. Prohibited at all times.

        Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
        Molecular weight
        1302.4 g/mol
        Sequence length
        14 chars
        CAS number
        374675-21-5
        PubChem CID
        25240297
        Compound class
        Decapeptide corresponding to the C-terminal region of human kisspeptin (metastin residues 45–54)
        Sequence
        YNWNSFGLRF-NH2
        Molecular formula
        C63H83N17O14
        Molecular weight
        1302.4 g/mol
        CAS number
        374675-21-5
        PubChem CID
        25240297